Literature DB >> 30565388

Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.

T L Slobodianuk1,2, C Kochelek1,2, J Foeckler3, S Kalloway3, H Weiler1, V H Flood1,2,4.   

Abstract

Essentials Defective binding to collagen IV has been seen in von Willebrand factor (VWF) A1 domain variants. We developed a murine model of defective VWF-collagen IV interactions with VWF variant p.R1399H. p.1399HH homozygous mice had decreased binding to collagen IV and increased bleeding times. p.1399HH homozygous mice had increased time to thrombosis and decreased platelet adhesion.
SUMMARY: Background von Willebrand factor (VWF) binding to type IV collagen occurs via the VWF A1 domain, with p.R1399H being the most common VWF variant affecting this interaction. Objectives We generated a murine model of 1399H VWF to investigate its in vivo effects. Methods Mice expressing the murine 1399H variant were generated via gene targeting in embryonic stem cells. VWF antigen and VWF collagen binding were measured with ELISA. Tail bleeding time assays were performed by clipping a 3-mm segment. Ferric chloride-induced thrombosis was measured via ultrasound in the carotid artery. Platelet aggregation in response to collagens I and IV was measured. VWF-dependent platelet adhesion to collagen IV was measured under flow. Results Breeding of heterozygous p.R1399H and homozygous p.1399HH mice was observed to follow normal Mendelian ratios. No spontaneous bleeding was observed for any of the offspring. VWF expression was normal, but VWF binding to collagen IV was decreased in both heterozygous and homozygous offspring. Blood loss following tail resection was increased for p.1399HH mice, and occlusion times following ferric chloride-induced thrombosis were prolonged. Platelet aggregation was unaffected, but platelet adhesion to collagen IV under flow was diminished for p.1399HH mice. Conclusions These results show that a decrease in the ability of 1399H VWF to bind collagen IV under static conditions corresponds to a decrease in binding under flow conditions, an increased bleeding time, and a prolonged time to thrombosis. This study supports the potential for a bleeding phenotype in patients with aberrant VWF-collagen IV binding.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  bleeding; collagen; thrombosis; von Willebrand disease; von Willebrand factor

Year:  2018        PMID: 30565388      PMCID: PMC6743498          DOI: 10.1111/jth.14341

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  31 in total

1.  150-kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen.

Authors:  J H Rand; N D Patel; E Schwartz; S L Zhou; B J Potter
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Characterization of a mouse model for thrombomodulin deficiency.

Authors:  H Weiler; V Lindner; B Kerlin; B H Isermann; S B Hendrickson; B C Cooley; D A Meh; M W Mosesson; N W Shworak; M J Post; E M Conway; L H Ulfman; U H von Andrian; J I Weitz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-09       Impact factor: 8.311

Review 3.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

4.  Structure of the gene for human von Willebrand factor.

Authors:  D J Mancuso; E A Tuley; L A Westfield; N K Worrall; B B Shelton-Inloes; J M Sorace; Y G Alevy; J E Sadler
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

5.  Role of COL4A1 in small-vessel disease and hemorrhagic stroke.

Authors:  Douglas B Gould; F Campbell Phalan; Saskia E van Mil; John P Sundberg; Katayoun Vahedi; Pascale Massin; Marie Germaine Bousser; Peter Heutink; Jeffrey H Miner; Elisabeth Tournier-Lasserve; Simon W M John
Journal:  N Engl J Med       Date:  2006-04-06       Impact factor: 91.245

6.  Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.

Authors:  A S Ribba; I Loisel; J M Lavergne; I Juhan-Vague; B Obert; G Cherel; D Meyer; J P Girma
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

7.  Cloning of the cDNA for murine von Willebrand factor and identification of orthologous genes reveals the extent of conservation among diverse species.

Authors:  Mohan S Chitta; Roy J Duhé; John C Kermode
Journal:  Platelets       Date:  2007-05       Impact factor: 3.862

8.  A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.

Authors:  C Denis; N Methia; P S Frenette; H Rayburn; M Ullman-Culleré; R O Hynes; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 9.  A database of polymorphisms in the von Willebrand factor gene and pseudogene. For the Consortium on von Willebrand Factor Mutations and Polymorphisms and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Authors:  J E Sadler; D Ginsburg
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

10.  Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor.

Authors:  H Lankhof; Y P Wu; T Vink; M E Schiphorst; H G Zerwes; P G de Groot; J J Sixma
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

View more
  1 in total

1.  von Willebrand factor variant D1472H has no effect in mice with humanized VWF-platelet interactions.

Authors:  Hannah K Lohmeier; Tricia L Slobodianuk; Sachiko Kanaji; Sandra L Haberichter; Robert R Montgomery; Veronica H Flood
Journal:  Blood Adv       Date:  2020-09-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.